宁波天益医疗器械股份有限公司的主营业务是血液净化及病房护理领域医用高分子耗材等医疗器械的研 发、生产与销售。公司的主要产品是血液净化装置的体外循环血路、一次性使用动静脉穿刺器、血液透 析浓缩液/血液透析干粉、一次性使用一体式吸氧管、喂食器及喂液管。 最新一期业绩显示，2025年三季报，公司实现营业收入3.87亿元，同比增加24.14%；净利润2009.41万 元，同比增加216.81%，销售毛利率38.39%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13天益医疗267.24-4672.432.9434.76亿行业平均 51.6852.394.44110.26亿行业中值40.1037.172.7757.10亿1九安医疗10.1811.530.87192.38亿2康德莱 15.5917.651.4238.00亿3英科医疗15.9818.571.50272.09亿4奥美医疗16.1319.791.9672.95亿5维力医疗 16.3018.152.0639.81亿6安杰思17.5716.351.9347.96亿7山东药玻17.6814.341.66135.24亿8新华医疗 17.8813.161.1 ...

天益医疗融资融券信息显示，融资方面，当日融资买入469.49万元，融资偿还490.04万元，融资净偿还 20.55万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量0.0股，融券余额0.0万元。融资融券 余额5047.81万元。 近5日融资融券数据一览见下表： | 日期 | 涨跌幅 | 融资余额(元) | 融资净买入(元) 融券余量(股) | | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-11-26 | 2.17% | 5047.81万 | -20.55万 | 0.0 | 0.0 | 5047.81万 | | 2025-11-25 | 0.18% | 5068.36万 | -390.20万 | 0.0 | 0.0 | 5068.36万 | | 2025-11-24 | 1.80% | 5458.56万 | -226.08万 | 0.0 | 0.0 | 5458.56万 | | 2025-11-21 | -5.93% | 5684.64万 | -506.13万 | 0.0 | 0.0 | 5684 ...

（文章来源：证券日报） 证券日报网讯天益医疗11月24日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东数 为5206户。 ...

Core Viewpoint - Tianyi Medical's subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate product [2] Group 1 - The product is officially recognized as a medical device, indicating compliance with regulatory standards [2] - This approval may enhance the company's market position in the medical device sector, particularly in dialysis treatment [2]

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a Medical Device Registration Certificate from the National Medical Products Administration for its subsidiary Ningbo Tianyi Pharmaceutical Technology Co., Ltd, enhancing its product portfolio and competitive edge in the market [1]. Group 1: Product Registration Details - The registered product is a blood dialysis concentrate, classified as a Class III medical device, with a registration number of Guo Xie Zhu Zheng 2025310230, valid from November 13, 2025, to November 12, 2030 [2]. - The blood dialysis concentrate consists of two components: A concentrate (A liquid) and a connected dry powder (B powder), designed to meet the personalized treatment needs of patients with acute and chronic renal failure [2]. - A liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate, utilizing acetic acid as a buffer in a medium calcium formulation [2]. Group 2: Strategic Implications - The acquisition of the medical device registration certificate extends the company's product chain and enriches its product categories, which is beneficial for enhancing the company's overall competitiveness in the healthcare market [2].

Core Viewpoint - Tianyi Medical (301097) announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which is intended for the treatment of acute and chronic renal failure patients undergoing hemodialysis [1] Company Summary - Tianyi Medical's subsidiary has successfully obtained regulatory approval for a new medical product, indicating progress in its product development and potential market entry [1] - The blood dialysis concentrate is specifically designed for patients with renal failure, highlighting the company's focus on addressing critical healthcare needs [1] Industry Summary - The approval of the blood dialysis concentrate aligns with the growing demand for renal care solutions, particularly in the context of increasing incidences of kidney-related diseases [1] - This development may enhance competition within the medical device sector, particularly in the field of dialysis treatment [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which includes A concentrate and B powder, enhancing its product offerings and competitive edge in the market [1] Group 1 - Tianyi Pharmaceutical, a subsidiary of Tianyi Medical, has obtained a medical device registration certificate for its blood dialysis concentrate [1] - The blood dialysis concentrate consists of A liquid, which includes sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, and B powder, which contains sodium bicarbonate [1] - The combination of A liquid and B powder offers advantages of both types of concentrates, catering to personalized clinical treatment needs [1] Group 2 - The acquisition of the registration certificate extends the company's product chain and enriches its product categories [1] - This development is expected to enhance the overall competitiveness of the company in the medical device industry [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate product, which enhances its product line and competitiveness in the market [1] Group 1: Product Details - The registered blood dialysis concentrate consists of two components: A concentrate (A liquid) and a connected dry powder (B powder) [1] - A liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate [1] - This combination of A liquid and B powder leverages the advantages of both types of concentrates, catering to personalized clinical treatment needs [1] Group 2: Strategic Implications - The acquisition of the medical device registration certificate extends the company's product chain and enriches its product categories [1] - This development is expected to enhance the company's overall competitiveness in the healthcare market [1]

证券代码： 301097 证券简称：天益医疗 公告编号：2025-063 宁波天益医疗器械股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）子公司宁波天益药业 科技有限公司（以下简称"天益药业"）于近日收到国家药品监督管理局颁发的 《医疗器械注册证》，具体情况如下： 一、产品注册证具体情况 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 国械注准 | | 2025 | 年 11 13 | 月 | 日至 | 用于急、慢性肾功 | | 1 | 血液透析浓缩物 | 2025310230 | III | | | | | 能 衰竭 患者 的 血 | | | | | | 2030 | 年 11 月 | | 12 日 | | | | | 3 | | | | | | 液透析治疗。 | 二、对公司的影响 ...